Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucocorticoid osteoporosis.

Philip N Sambrook1

  • 1Institute of Bone & Joint Research, University of Sydney, Sydney, Australia. mchurchi@doh.health.nsw.gov.au

Current Pharmaceutical Design
|August 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of IDUA and WNT16 Phosphorylation-Related Non-Synonymous Polymorphisms for Bone Mineral Density in Meta-Analyses of Genome-Wide Association Studies.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2015
Same author

Identification of a novel FGFRL1 MicroRNA target site polymorphism for bone mineral density in meta-analyses of genome-wide association studies.

Human molecular genetics·2015
Same author

Vitamin D response of older people in residential aged care to sunlight-derived ultraviolet radiation.

Archives of osteoporosis·2014
Same author

Weight and fat distribution in patients taking valproate: a valproate-discordant gender-matched twin and sibling pair study.

Epilepsia·2014
Same author

Medication safety in residential aged-care facilities: a perspective.

Therapeutic advances in drug safety·2014
Same author

Multistage genome-wide association meta-analyses identified two new loci for bone mineral density.

Human molecular genetics·2013

Postmenopausal women on glucocorticoids need bone loss prevention. Bisphosphonates are the preferred treatment, with vitamin D or hormone replacement therapy as alternatives for preventing fractures.

Area of Science:

  • Endocrinology
  • Osteoporosis Research
  • Pharmacology

Background:

  • Glucocorticoids are widely used medications with significant side effects.
  • Glucocorticoid therapy is associated with accelerated bone loss and increased fracture risk, particularly in postmenopausal women.
  • Current guidelines for initiating bone protective therapy in patients on glucocorticoids are not always clear, especially for men and premenopausal women.

Purpose of the Study:

  • To review the evidence regarding bone loss and fracture risk in patients receiving glucocorticoids.
  • To provide recommendations for prophylactic measures to prevent glucocorticoid-induced osteoporosis.
  • To establish an evidence-based order of choice for anti-osteoporosis therapies.

Main Methods:

  • Systematic review of existing literature on glucocorticoid-induced bone loss and fracture risk.

Related Experiment Videos

  • Analysis of clinical trial data and expert consensus on osteoporosis prophylaxis.
  • Evaluation of the efficacy of various treatment options, including bisphosphonates, vitamin D, hormone replacement therapy, and calcium.

    • Main Results:

    • Postmenopausal women on glucocorticoids are at the highest risk and warrant prophylactic treatment.
    • For men and premenopausal women, prophylaxis decisions depend on baseline bone mineral density (BMD), glucocorticoid dose, and duration.
    • Bisphosphonates are the first-line choice, followed by vitamin D metabolites or hormone replacement therapy (HRT). Calcium alone is insufficient.
    • HRT is recommended for patients with hypogonadism. Calcium and vitamin D may suffice for chronic low-dose glucocorticoid users, but therapies increasing BMD reduce fracture risk.

    Conclusions:

    • Prophylactic measures are crucial for postmenopausal women initiating glucocorticoid therapy.
    • Treatment choice for glucocorticoid-induced osteoporosis should be individualized based on patient-specific factors and risk assessment.
    • Bisphosphonates represent the primary therapeutic option, with vitamin D and HRT as viable alternatives, especially in cases of hypogonadism.